ProtAffin has developed the CellJammer® discovery technology to generate a pipeline of glycan-binding decoy proteins with applications in respiratory medicine, inflammation and oncology. By pioneering biologics targeting glycans, ProtAffin offers a comprehensive and novel platform of biological products to optimally address a large number of protein targets that naturally bind glycans.
ProtAffin’s lead product is PA401, a glycan-binding decoy protein based on interleukin-8 (IL-8). PA401 is in preclinical development for chronic obstructive pulmonary disease (COPD), the 4th leading cause of death in the western world. PA401 also has potential applications in other diseases where chronic neutrophil infiltration is seen in the lung.
Latest news
PA401
ProtAffin’s most advanced product candidate is PA401, a glycan-binding decoy protein based on IL-8. Using our CellJammer® discovery platform, we have modified human IL-8 to act as a targeted anti-inflammatory product.
CellJammer® platform
The CellJammer® discovery platform generates glycan-binding decoy proteins in inflammation and oncology. It is a novel biologics platform alternative to mAb and scaffold technologies as well as to glycan-based approaches like heparin.
Partnering
ProtAffin is actively seeking collaborations with biotechnology and pharmaceutical companies to use the CellJammer® discovery platform to target protein-glycan interactions using decoy proteins.
Team
ProtAffin has 24 employees and is located in Graz, Austria and London, UK. ProtAffin is supported by government grants and a renowned syndicate of international venture capital investors.